biostudies-literatureGoldvaser HNCI NIH HHS167-177https://www.ebi.ac.uk/biostudies/studies/S-EPMC12353014biostudies-literatureUnknown210(1)<h4>Purpose</h4>To evaluate the association between the HER2 score as provided by the Oncotype DX Recurrence Score (RS) assay, tumor characteristics, and outcomes in early-stage, ER + HER2-negative breast cancer (BC).<h4>Methods</h4>All women insured by the Clalit Health Services, with early-stage, ER + HER2-negative BC who underwent RS testing between 2008 and 2011 were included. Patient/tumor characteristics and Kaplan-Meier estimates for distant recurrence-free survival (DRFS) and overall survival (OS) were compared by HER2 category, based on the HER2 score provided by the RS assay: lower HER2 score group representing the lower third of the HER2 score range (≤ 8.5); higher HER2 score group representing the upper 2 thirds of the HER2 score range (8.6-10.7).<h4>Results</h4>1535 patients wBreast cancer research and treatmentER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes.PMC12353014P30 CA008748Drumea KEvron EToker MGal-Yam ESela GBYerushalmi RMutai RPaluch-Shimon SMerose RShai ASonnenblick ASoussan-Gutman LStemmer SMBareket-Samish AGoldvaser HKuchuk IfalseER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes.<h4>Purpose</h4>To evaluate the association between the HER2 score as provided by the Oncotype DX Recurrence Score (RS) assay, tumor characteristics, and outcomes in early-stage, ER + HER2-negative breast cancer (BC).<h4>Methods</h4>All women insured by the Clalit Health Services, with early-stage, ER + HER2-negative BC who underwent RS testing between 2008 and 2011 were included. Patient/tumor characteristics and Kaplan-Meier estimates for distant recurrence-free survival (DRFS) and overall survival (OS) were compared by HER2 category, based on the HER2 score provided by the RS assay: lower HER2 score group representing the lower third of the HER2 score range (≤ 8.5); higher HER2 score group representing the upper 2 thirds of the HER2 score range (8.6-10.7).<h4>Results</h4>1535 patients w2025-01-01T00:00:00Z2025 Feb2026-05-29T15:08:32.28Z2026-04-08T05:11:47.514ZS-EPMC123530143956082210.1007/s10549-024-07549-7